Empowered Funds LLC Purchases Shares of 56,357 Doximity, Inc. (NASDAQ:DOCS)

Empowered Funds LLC acquired a new position in shares of Doximity, Inc. (NASDAQ:DOCS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 56,357 shares of the company’s stock, valued at approximately $3,009,000.

A number of other large investors have also made changes to their positions in DOCS. FMR LLC boosted its stake in Doximity by 30.5% during the third quarter. FMR LLC now owns 6,837,733 shares of the company’s stock worth $297,920,000 after buying an additional 1,598,602 shares in the last quarter. State Street Corp lifted its holdings in shares of Doximity by 2.5% during the 3rd quarter. State Street Corp now owns 3,693,982 shares of the company’s stock worth $160,947,000 after acquiring an additional 88,922 shares during the period. Geode Capital Management LLC boosted its position in shares of Doximity by 19.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company’s stock valued at $124,503,000 after acquiring an additional 472,565 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Doximity by 4.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 753,001 shares of the company’s stock valued at $32,808,000 after acquiring an additional 31,966 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new position in Doximity in the third quarter worth about $29,453,000. Institutional investors and hedge funds own 87.19% of the company’s stock.

Insider Transactions at Doximity

In other news, Director Timothy S. Cabral sold 20,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now owns 6,360 shares of the company’s stock, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 37.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DOCS. The Goldman Sachs Group upped their price objective on Doximity from $58.00 to $80.00 and gave the company a “neutral” rating in a research note on Monday. KeyCorp lowered their price target on Doximity from $70.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Canaccord Genuity Group cut Doximity from a “buy” rating to a “hold” rating and lifted their price objective for the company from $40.00 to $60.00 in a report on Wednesday, November 13th. Mizuho boosted their target price on shares of Doximity from $55.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday. Finally, JPMorgan Chase & Co. increased their target price on shares of Doximity from $30.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $64.22.

Doximity Stock Performance

NASDAQ:DOCS opened at $76.68 on Friday. The company has a market cap of $14.31 billion, a price-to-earnings ratio of 76.68, a P/E/G ratio of 4.61 and a beta of 1.39. The stock’s fifty day moving average price is $57.46 and its two-hundred day moving average price is $47.03. Doximity, Inc. has a 52-week low of $22.96 and a 52-week high of $85.21.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.